{
  "docId": "019de076-b279-75da-94b2-8ad8944b7652",
  "docSlug": "3080df08d7a75d95f523d4df26f037ae",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 29,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a chevron-based process flow to represent maturity stages.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b279-75da-94b2-8ad8944b7652/20",
  "deckHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652",
  "deckJsonHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652.json",
  "deckAnchorHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.92,
        "x": 0.04,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "PROVEN, UNDER EVALUATION, FUTURE",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e5dca71-d942-4de3-a7da-18067bc7a256",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.58,
        "y": 0.35
      },
      "kind": "list",
      "text": "Potential Therapeutic Applications: INFECTION (Anti-infectives, Antivirals), INFLAMMATION (Autoimmune, Neuro-inflammatory, Acute/chronic), ONCOLOGY (Hematologic & solid tumor)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3599ad28-9b0d-47a5-bc3a-3916381a6692",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.31,
        "y": 0.5
      },
      "kind": "list",
      "text": "Intracellular Delivery of Nucleic Acids: siRNA, ASO",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7789bb48-6387-4130-a01f-12f7f5c5b7d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "Oral Formulations of Anti-Infectives: MAT2203, Remdesivir, MAT2501. Oral Formulations of Chemotherapeutics: Docetaxel",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c74fb1b4-ea81-46a1-bec0-3d5b9adb0dcc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.1,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Matinas is working internally and with third parties to broaden its pipeline of LNC-based therapeutics",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e05c72e-9b9a-4f34-9864-b73ba7a2f37d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.32,
        "x": 0.34,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "* Key Areas of Focus for Internal LNC Oral Small Oligonucleotides",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0a7ce5b-2be8-4c15-9e36-3e63804673bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.52,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Unlocking the Full Potential of the LNC Platform",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b95312f-132f-4de9-b9d5-a427a8f9ed9c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "452ea412-fe5e-4720-82f9-18873e3facc7",
      "evidence": "Chevron-based progression from Proven to Future",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}